CINECA IRIS Institutional Research Information System

CATTEL, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.919
NA - Nord America 12.550
AS - Asia 4.230
AF - Africa 55
SA - Sud America 53
Continente sconosciuto - Info sul continente non disponibili 49
OC - Oceania 22
Totale 30.878
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.341
IT - Italia 6.210
CN - Cina 1.793
IE - Irlanda 1.396
SE - Svezia 1.277
DE - Germania 1.034
FR - Francia 1.026
SG - Singapore 938
FI - Finlandia 831
UA - Ucraina 812
KR - Corea 810
GB - Regno Unito 437
PL - Polonia 303
AT - Austria 249
JP - Giappone 210
VN - Vietnam 209
CA - Canada 184
IN - India 95
NL - Olanda 67
RU - Federazione Russa 65
BE - Belgio 54
EU - Europa 49
CH - Svizzera 46
IR - Iran 37
SN - Senegal 34
BR - Brasile 30
UZ - Uzbekistan 29
ES - Italia 27
IL - Israele 27
RO - Romania 25
HK - Hong Kong 24
MX - Messico 21
AU - Australia 19
ID - Indonesia 19
TR - Turchia 10
EC - Ecuador 9
CO - Colombia 6
CZ - Repubblica Ceca 5
GR - Grecia 5
PE - Perù 5
PH - Filippine 5
PT - Portogallo 5
AL - Albania 4
BY - Bielorussia 4
DZ - Algeria 4
GI - Gibilterra 4
MA - Marocco 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BG - Bulgaria 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
SM - San Marino 3
TH - Thailandia 3
TW - Taiwan 3
TZ - Tanzania 3
BF - Burkina Faso 2
CY - Cipro 2
DK - Danimarca 2
EG - Egitto 2
HU - Ungheria 2
LT - Lituania 2
LV - Lettonia 2
MU - Mauritius 2
NG - Nigeria 2
PA - Panama 2
RS - Serbia 2
ZA - Sudafrica 2
AF - Afghanistan, Repubblica islamica di 1
AR - Argentina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
MC - Monaco 1
MT - Malta 1
MY - Malesia 1
PK - Pakistan 1
SA - Arabia Saudita 1
Totale 30.878
Salva come PNG Salva come JPEG
Città #
Chandler 1.587
Dublin 1.374
Beijing 1.220
Santa Clara 880
Jacksonville 816
Ann Arbor 769
Singapore 697
Medford 433
Princeton 432
Houston 431
Dearborn 426
Villeurbanne 370
Columbus 367
Ashburn 308
Wilmington 298
Milan 296
Rome 291
Torino 283
Warsaw 274
Vienna 247
Nyköping 245
Fairfield 202
Boston 198
Dong Ket 160
Munich 157
Woodbridge 147
Boardman 137
Montréal 117
Fremont 87
Cambridge 86
Seattle 85
Pisa 75
Naples 73
Verona 73
New York 71
Hefei 67
Mcallen 64
Norwalk 60
Turin 60
Falls Church 56
Nanjing 54
Palermo 54
Guangzhou 53
Napoli 52
Bologna 45
Düsseldorf 42
Catania 40
Florence 40
Brussels 38
Kunming 38
San Mateo 38
Bari 36
Shanghai 35
Padova 33
Redwood City 33
Genova 30
Dallas 27
Mountain View 27
Toronto 27
Washington 27
Nanchang 25
Hangzhou 23
Jinan 23
Zhengzhou 23
Helsinki 22
Parma 22
Tel Aviv 21
Brescia 20
Des Moines 19
Jakarta 19
Mumbai 19
Hong Kong 18
Seongnam 18
Lachine 17
Pescara 17
Fuzhou 16
Genoa 16
Hebei 16
Pune 16
Trieste 16
Menlo Park 15
Philadelphia 15
Phoenix 14
Los Angeles 13
Messina 13
Moscow 13
Shenyang 13
Chongqing 12
Taranto 12
Massa 11
Missaglia 11
Monza 11
San Diego 11
Sassari 11
Wuhan 11
Cinisello Balsamo 10
Frankfurt am Main 10
Frattamaggiore 10
Grafing 10
London 10
Totale 15.410
Salva come PNG Salva come JPEG
Nome #
Somministrazione intravescicale di Mitomicina C in ipertermia nei carcinomi vescicali superficiali a rischio intermedio 3.679
L'alcol etilico nei farmaci chemioterapici antiblastici iniettabili: valutazioni ed implicazioni pratiche 1.704
Cationic liposomes contaiing a DOPE-hyaluronic acid conjugate for gene delivery 382
A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"? 350
PEGylation of proteins and liposomes, a powerful and flexible strategy to improve the drug delivery 302
Pharmacokinetic study to optimize the intravesical administration of gemcitabine 292
Caratterizzazione di nanoparticelle di polialchilcianoacrilato coniugate con l’acido folico 261
Farmacocinetica del paclitaxel in associazione con acido valproico nella terapia del tumore anaplastico della tiroide 226
Farmaci macromolecolari: veicolazione e direzionamento mediante albumina umana 193
Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. 187
Messa a punto del metodo di estrazione e determinazione analitica, tramite HPLC, dell'amfotericina B su campioni ematici 184
Preparazione e caratterizzazione di liposomi convenzionali ed a lunga circolazione contenenti taxani 167
A unique squalenoylated and non pegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity 161
Stereospecific synthesis of squalenoid epoxide vinyl ethers as inhibitors of 2,3-oxidosqualene cyclase. 156
Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives. 155
Ruthenium polypyridyl squalene derivative: a novel self-assembling lipophilic probe for cellular imaging 154
A Pharmacokinetics Study to Optimize Intravesical Administration of Gemcitabine 146
Stereospecific synthesis of squalenoid epoxide vinyl ethers as inhibitors of 2,3-oxidosqualene cyclase 146
Hyaluronic acid-coated liposomes for active targeting of gemcitabine. 144
10 and 19-azasqualene derivatives as irreversible inhibitors of 2,3-oxidosqualene cyclase from pig liver. 141
Vaccini, sieri, immunoglobuline e anticorpi monoclonali 131
Sintesi di inibitori suicidi dello squalene 2,3-epossido ciclasi. 126
Use of squalenic acid for the formulation of an active principle in nanoparticle state 121
Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits 120
The role of conjugation processes and crosslinking agent in the preparation of molecular/particulate conjugates: a review 111
Immunotossina AR3-ricina: comportamento farmacocinetico, biodistribuzione ed efficacia terapeutica in topi nudi portatori di adenocarcinoma umano 110
Alternate scheduling of Gemcitabine (GEM) - Oxaliplatin (OXA) association in metastatic (MTS) or locally advanced (LA) pancreatic adenocarcinoma: a clinical and pharmacokinetic (pk) evaluation 110
Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry 108
Nanoparticles of therapeutic agents having low water solubility 108
Farmacocinetica della Gemcitabina (GEM) e del suo trifosfato (dFdCTP) in infusione prolungata a basse dosi in monochemioterapia in pazienti affetti da tumori solidi 106
Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique 103
Preparazione e caratterizzazione di liposomi convenzionali e a lunga circolazione contenenti taxani 103
Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate 102
PHARMACOKINETICS, PHARMACOLOGICAL STABILITY, SAFETY AND ACTIVITY OF MMC ADMINISTERED WITH A NEW HYPERTHERMIA DEVICE (UNITHERMIA) 101
A new 'blocked' immunotoxin 97
A pharmacokinetics study to optimize intravesical administration of gemcitabine 97
Anticancer prodrugs: an overview of major strategies and recent developments. 96
Vinyl sulfide derivatives of truncated oxidosqualene as selective inhibitors of oxidosqualene and squalene-hopene cyclases 95
Synthesis and biological activity of 22,23-epoxy-2-aza-2,3-dihydrosqualene derivatives: potent new inhibitors of squalene 2,3-oxide - lanosterol cyclase. 95
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. 95
Veicolazione del paclitaxel mediante anticorpi monoclonali, macromolecole, liposomi 94
Biological characterization of folic acid-conjugated poly(H(2)NPEGCA-co-HDCA) nanoparticles in cellular models 93
Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck - Pharmacokinetic and clinical data of a phase I-II study 93
Active targeting of squalenic nanoparticles 93
Farmacocinetica dell’associazione di vinorelbina orale con doxorubicina liposomiale peghilata nel tumore mammario metastatico 93
Synthesis of a squalenoid oxaziridine and other new classes of squalene derivatives, as inhibitors of sterol biosynthesis. 91
2,3-oxidosqualene cyclase and squalene epoxidase, as target enzymes for the development of new sterol biosynthesis inhibitors 91
A new "solid phase" procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates). 91
Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines 90
29-methylidene-2,3-oxidosqualene derivatives as stereospecific mechanism-based inhibitors of liver and yeast oxidosqualene cyclase. 90
Characterisation of folic acid-nanoparticles conjugates for tumoral targeting 90
19-azasqualene-2,3-epoxide and its N-oxide: metabolic fate and inhibitory effect on sterol biosynthesis in Saccharomyces cerevisiae 87
2,3-oxidosqualene cyclase and squalene epoxidase: enzymology, mechanism and inhibitors 87
Azasqualeni N-ossidi e bis-azasqualeni, inibitori dell'enzima squalene epossido ciclasi. 87
Targeting of squalene nanoparticles 86
New DSPE-PEG-Folate conjugates for liposomal drug targeting 86
Veicolazione del paclitaxel e di sue prodrugs idrofile in liposomi ed immunoliposomi. 86
Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components 86
Pharmacokinetics, Pharmacological Stability, Safety and Efficacy of MMC Administered with a New Hyperthermia Device 86
N-oxide as a potential function in the design of enzyme inhibitors. Application to 2,3-epoxysqualene-sterol cyclases. 86
A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions 85
Veicolazione di taxani in liposomi convenzionali ed a lunga circolazione 85
Characterization and partial purification of squalene-2,3-oxide cyclase from Saccharomyces cerevisiae. 84
2-Aza-2,3-dihydrosqualene: biodistribution and pharmacokinetic properties in mice. 84
2,3-oxidosqualene cyclase and squalene epoxidase, as target enzymes for the development of new sterol biosynthesis inhibitors. 83
2,3-oxidosqualene cyclase: from azasqualenes to new site-directed inhibitors. 83
2,3,4,5-Tetrahydroxy-5-(4-hydroxyphenyl)valeric acid: a new cleavable monofunctional reagent for monoclonal antibody labeling. 83
Squalenizzazione: nuova tecnica per nanoparticelle non polimeriche. 82
Studio dell'attività antitumorale 'in vitro' ed 'in vivo' di un'immunotossina anticorpo-ricina ad alta specificità 82
Design of specific tools to evaluate the Cost Of Illness (COI) of Rheumatoid Arthritis 82
Synthesis of squalenoid acetylenes and allenes, as inhibitors of squalene epoxidase. 82
The squalene-2,3-epoxide cyclase as a model for the development of new drugs. 81
Biological characterisation of folic acid-conjugated nanoparticles in cellular models 81
An original approach to conjugate monoclonal antibody and cytotoxic proteins in heterogeneous phase 81
Cationic liposomes contaiing a DOPE-hyaluronate conjugate for gene delivery 81
Novel potent doxorubicin derivatives able to self nanoassembly 81
Farmacocinetica della somministrazione alternata della Gemcitabina (GEM) e Oxaliplatino (OXA) nei tumori pancreatici e delle vie biliari 81
Association of Gemcitabine (GEM) and Oxaliplatin (OXA) in metastatic or locally advanced pancreatic adenocarcinoma: a clinical and pharmacokinetic (PK) study 81
Coagulation Factor VIII: pharmacoeconomic evaluation and quality of life as measuring tools in clinical practice 81
A convenient synthesis of [3-3H]squalene and [3-3H]-2,3-oxidosqualene. 81
Hyaluronic acid-modified liposomes: preparation and preliminary biological characterization 80
Synthesis, characterization and biological evaluation of new PEG-paclitaxel derivatives. 80
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential 80
Gemcitabine derivatives nanoparticles 79
Synthesis of HEI analogues of the C-20 carbocation forming during lanosterol biosynthesis, as hypocholesterolemics. 79
Total synthesis of the hypocholesterolemic and antifungal drug 10-azasqualene 2,3-epoxide, the first non-cyclized analogue of the C-8 carbonium ion formed during squalene epoxide cyclization. 79
Antibody-targeted leucinostatin A 79
Production and characterization of a monoclonal antibody reactive on the 2,3-epoxysqualene cyclase 79
2,3-Oxidosqualene cyclase and squalene epoxidase as target enzymes for the development of new sterol biosynthesis inhibitors 79
Synthesis, characterization and biological activity of new cationic lipids active for gene transfection. 78
2,3-Oxidosqualene cyclase: from azasqualenes to new site-directed inhibitors. 78
A new approach in the synthesis of immunotoxins: ribosome inactivating protein noncovalently bound to monoclonal antibody. 78
Synthesis of new gemcitabine prodrugs for liposome and nanoparticle encapsulation 78
Nonpolymeric nanoparticles for ocular administration of acyclovir 78
Administration of reduced glutathione in FOLFOX4 regimen in advanced colorectal cancer: effect on oxaliplatin pharmacokinetics and on Pt-DNA adducts formation 78
Paclitaxel e doxorubicina liposomiale peghilata in tumori testa/collo recidivanti: un’inaspettata interazione farmacocinetica intervallo-dipendente relativa alla somministrazione 78
Studio Farmacocinetico per determinare la modalità di somministrazione più idonea per la gemcitabina endovescicale 78
A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck 78
2,3-Epoxy-10-aza-10,11-dihydrosqualene, a high-energy intermediate analogue inhibitor of 2,3-oxidosqualene cyclase. 77
Veicolazione ed attività antitumorale di derivati della 5-fluorouridina mediante anticorpi monoclonali 77
Totale 16.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.407
article - articoli 0
book - libri 0
conference - conferenze 50.433
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.840
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.088 0 0 0 0 0 0 507 208 481 354 292 246
2020/20213.825 533 196 255 236 412 215 342 157 429 301 342 407
2021/20223.819 114 103 116 229 276 123 235 352 103 203 932 1.033
2022/20235.290 604 339 125 529 503 1.398 536 312 485 85 253 121
2023/20242.108 252 363 150 122 110 209 66 96 28 120 198 394
2024/20253.050 103 367 154 583 1.532 302 9 0 0 0 0 0
Totale 31.989